Indium (111In) biciromab
| Monoclonal antibody | |
|---|---|
| Type | Fab' fragment |
| Source | Mouse |
| Target | Fibrin II, beta chain |
| Clinical data | |
| Trade names | FibriScint |
| Pregnancy category |
|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
  (what is this?) (verify) | |
Indium (111In) biciromab (INN, trade name FibriScint, developed by Centocor) was a drug targeting fibrin, a protein involved in the clotting of blood.[1] It was the Fab' fragment of a mouse monoclonal antibody labelled with the radioisotope indium-111 for the diagnosis of thromboembolism,[2] but was withdrawn during clinical trials.[3]
References
- ^ King, David J.; John R. Adair (1999). "Recombinant antibodies for the diagnosis and therapy of human disease". Current Opinion in Drug Discovery & Development. 2 (2): 112. ISSN 1367-6733.
- ^ Answers.com: Centocor Ortho Biotech Products, L.P.
- ^ DiagnosticImaging.com: Centocor withdraws imaging agent applications
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |